Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insmed (INSM) Short-term Investments (2022 - 2026)

Insmed's Short-term Investments history spans 9 years, with the latest figure at $641.3 million for Q1 2026.

  • Quarterly Short-term Investments fell 19.45% to $641.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $641.3 million through Mar 2026, down 19.45% year-over-year, with the annual reading at $919.6 million for FY2025, 4.64% up from the prior year.
  • Short-term Investments came in at $641.3 million for Q1 2026, down from $919.6 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $1.3 billion in Q3 2025 to a low of $29.8 million in Q1 2023.
  • The 5-year median for Short-term Investments is $304.9 million (2023), against an average of $501.5 million.
  • The largest YoY upside for Short-term Investments was 301.48% in 2023 against a maximum downside of 75.07% in 2023.
  • Insmed's Short-term Investments stood at $74.2 million in 2022, then soared by 301.48% to $298.1 million in 2023, then surged by 194.83% to $878.8 million in 2024, then grew by 4.64% to $919.6 million in 2025, then plummeted by 30.26% to $641.3 million in 2026.
  • Per Business Quant, the three most recent readings for INSM's Short-term Investments are $641.3 million (Q1 2026), $919.6 million (Q4 2025), and $1.3 billion (Q3 2025).